ERYTECH announces that the data related to GRASPA® Phase 3 pivotal program in Acute Lymphoblastic Leukemia (ALL) will be the subject of oral presentations at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2, Chicago, USA, and at the 20th Congress of European Hematology, June 11 – 14, Vienna, Austria. A poster on the design of the ongoing Phase IIb study in Acute Myeloid Leukemia (AML) will also be presented at ASCO.
